Charles N Bernstein1, Lixia Zhang2, Lisa M Lix2, Lesley A Graff3, John R Walker3, John D Fisk4, Scott B Patten5, Carol A Hitchon1, James M Bolton6, Jitender Sareen6, Renée El-Gabalawy3,7, James Marriott1, Ruth Ann Marrie1,2. 1. Department of Internal Medicine, University of Manitoba, Winnipeg, Canada. 2. Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada. 3. Department of Clinical Health Psychology, University of Manitoba, Winnipeg, Canada. 4. Nova Scotia Health Authority, Departments of Psychiatry, Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax, Canada. 5. Departments of Community Health Sciences and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada. 6. Department of Psychiatry, University of Manitoba, Winnipeg, Canada. 7. Departments of Anesthesia and Perioperative Medicine, Max Rady College of Medicine Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Abstract
BACKGROUND: We evaluated the validity and reliability of multiple symptom scales for depression and anxiety for persons with inflammatory bowel disease (IBD). METHODS: IBD participants in a cohort study completed a Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) and completed the Patient Health Questionnaire (PHQ-9), Hospital Anxiety and Depression Scale (HADS), Kessler-6 Distress Scale, PROMIS Emotional Distress Depression Short-Form 8a (PROMIS Depression) and Anxiety Short-Form 8a (PROMIS Anxiety), Generalized Anxiety Disorder 7-item Scale, and Overall Anxiety and Severity Impairment Scale. We computed sensitivity, specificity, and positive and negative predictive values for the screening measures with the SCID diagnoses as the reference standard, conducted receiver operating curve (ROC) analysis, and assessed internal consistency and test-retest reliability. RESULTS: Of 242 participants, the SCID classified 8.7% as having major depression and 17.8% as having anxiety disorders. Among the depression scales, the PHQ-9 had the highest sensitivity (95%). Specificity was generally higher than sensitivity and was highest for the HADS-D (cut-point of 11; 97%). The area under the ROC curve (AUC) did not differ significantly among depression scales. Among the anxiety scales, sensitivity was highest for the PROMIS (79%). Specificity ranged from 82% to 88% for all tools except the HADS-A (cut-point of 8; 65%). The AUC did not differ between depression and anxiety tools. CONCLUSIONS: Overall, the symptom scales for depression and anxiety were similar in their psychometric properties. The anxiety scales did not perform as well as the depression scales. Alternate cut-points may be more relevant when these scales are used in an IBD sample.
BACKGROUND: We evaluated the validity and reliability of multiple symptom scales for depression and anxiety for persons with inflammatory bowel disease (IBD). METHODS: IBD participants in a cohort study completed a Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) and completed the Patient Health Questionnaire (PHQ-9), Hospital Anxiety and Depression Scale (HADS), Kessler-6 Distress Scale, PROMIS Emotional Distress Depression Short-Form 8a (PROMIS Depression) and Anxiety Short-Form 8a (PROMIS Anxiety), Generalized Anxiety Disorder 7-item Scale, and Overall Anxiety and Severity Impairment Scale. We computed sensitivity, specificity, and positive and negative predictive values for the screening measures with the SCID diagnoses as the reference standard, conducted receiver operating curve (ROC) analysis, and assessed internal consistency and test-retest reliability. RESULTS: Of 242 participants, the SCID classified 8.7% as having major depression and 17.8% as having anxiety disorders. Among the depression scales, the PHQ-9 had the highest sensitivity (95%). Specificity was generally higher than sensitivity and was highest for the HADS-D (cut-point of 11; 97%). The area under the ROC curve (AUC) did not differ significantly among depression scales. Among the anxiety scales, sensitivity was highest for the PROMIS (79%). Specificity ranged from 82% to 88% for all tools except the HADS-A (cut-point of 8; 65%). The AUC did not differ between depression and anxiety tools. CONCLUSIONS: Overall, the symptom scales for depression and anxiety were similar in their psychometric properties. The anxiety scales did not perform as well as the depression scales. Alternate cut-points may be more relevant when these scales are used in an IBD sample.
Authors: Murray B Stein; Peter P Roy-Byrne; Michelle G Craske; Alexander Bystritsky; Greer Sullivan; Jeffrey M Pyne; Wayne Katon; Cathy D Sherbourne Journal: Med Care Date: 2005-12 Impact factor: 2.983
Authors: Sunny Singh; Andrea Blanchard; John R Walker; Lesley A Graff; Norine Miller; Charles N Bernstein Journal: Clin Gastroenterol Hepatol Date: 2011-05-20 Impact factor: 11.382
Authors: Charles N Bernstein; Carol A Hitchon; Randy Walld; James M Bolton; Jitender Sareen; John R Walker; Lesley A Graff; Scott B Patten; Alexander Singer; Lisa M Lix; Renée El-Gabalawy; Alan Katz; John D Fisk; Ruth Ann Marrie Journal: Inflamm Bowel Dis Date: 2019-01-10 Impact factor: 5.325
Authors: Jonathan Savitz; Bart N Ford; Hung-Wen Yeh; Elisabeth Akeman; Kelly Cosgrove; Ashley N Clausen; Christopher Martell; Namik Kirlic; Jessica Santiago; T Kent Teague; Michael R Irwin; Martin P Paulus; Robin L Aupperle Journal: Psychol Med Date: 2020-11-25 Impact factor: 10.592
Authors: Ruth Ann Marrie; Lesley A Graff; John D Fisk; Scott B Patten; Charles N Bernstein Journal: Inflamm Bowel Dis Date: 2021-07-27 Impact factor: 5.325
Authors: Ruth Ann Marrie; Ronak Patel; Charles N Bernstein; James M Bolton; Lesley A Graff; James J Marriott; Carol A Hitchon; Chase R Figley; Jennifer Kornelsen; John D Fisk Journal: Mult Scler Date: 2020-09-25 Impact factor: 6.312
Authors: Gaurav Syal; Mariastella Serrano; Animesh Jain; Benjamin L Cohen; Florian Rieder; Christian Stone; Bincy Abraham; David Hudesman; Lisa Malter; Robert McCabe; Stefan Holubar; Anita Afzali; Adam S Cheifetz; Jill K J Gaidos; Alan C Moss Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325